For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.
We offer closed automated solutions for manual steps in the cell manufacturing process. Our flexible automated modules provide performance gains in purifying mononuclear cells, washing contaminants from cell fractions, cell selection, and storage while significantly shortening processing times.
Cell and gene therapies (CGT) are gaining greater popularity in the community as viable regenerative medicine options. Although there has been a lot of progress made in a relatively short amount of time, there are challenges to overcome before these treatments can become more mainstream. As a solution to the concerns with rapid, scalable manufacturing, … Continued
RANCHO CORDOVA, Calif., September 14, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant to develop and test the single-use sterile cell processing disposable, … Continued
The Importance of Cryopreservation in GMP Cell Therapy Cryopreservation is a process that preserves cells and tissues by freezing samples to very low temperatures over a period of time. It’s important to the cell therapy manufacturing process because cell samples need to be properly stored in order to maintain their viability and functionality later down … Continued
RANCHO CORDOVA, Calif., September 7, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. If you are an … Continued
Translating a drug from a concept to a treatment that is scalable and manufacturable can be the biggest challenge for developers of cell and gene therapies (CGT). Particularly in this field, the challenge is even greater because the people who are able to perform the necessary tasks need to be highly skilled cell biologists … Continued